Pieris Pharmaceuticals (PIRS) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of Pieris Pharmaceuticals (NASDAQ:PIRS) from a strong sell rating to a sell rating in a research report report published on Wednesday morning.

Several other brokerages have also recently weighed in on PIRS. ValuEngine cut Pieris Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Tuesday, May 29th. HC Wainwright set a $12.00 price target on Pieris Pharmaceuticals and gave the company a buy rating in a research report on Thursday, June 7th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. The company has a consensus rating of Buy and an average target price of $12.33.

Pieris Pharmaceuticals stock opened at $5.59 on Wednesday. Pieris Pharmaceuticals has a 52 week low of $4.43 and a 52 week high of $9.75. The stock has a market cap of $307.46 million, a P/E ratio of -13.98 and a beta of 1.62.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings results on Thursday, August 9th. The biotechnology company reported $0.00 earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.01). The company had revenue of $11.69 million for the quarter, compared to analysts’ expectations of $13.46 million. Pieris Pharmaceuticals had a negative net margin of 22.38% and a negative return on equity of 27.81%. analysts expect that Pieris Pharmaceuticals will post -0.49 EPS for the current fiscal year.

In related news, Director Christopher P. Kiritsy purchased 5,000 shares of Pieris Pharmaceuticals stock in a transaction that occurred on Friday, September 14th. The stock was bought at an average cost of $5.11 per share, for a total transaction of $25,550.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at $51,100. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 5.07% of the stock is currently owned by company insiders.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its position in shares of Pieris Pharmaceuticals by 49.1% in the second quarter. BlackRock Inc. now owns 2,685,490 shares of the biotechnology company’s stock valued at $13,616,000 after buying an additional 884,348 shares in the last quarter. Acadian Asset Management LLC increased its position in shares of Pieris Pharmaceuticals by 45.5% in the second quarter. Acadian Asset Management LLC now owns 2,124,873 shares of the biotechnology company’s stock valued at $10,773,000 after buying an additional 664,032 shares in the last quarter. Aquilo Capital Management LLC purchased a new stake in shares of Pieris Pharmaceuticals in the second quarter valued at approximately $10,013,000. Millennium Management LLC increased its position in shares of Pieris Pharmaceuticals by 160.7% in the first quarter. Millennium Management LLC now owns 1,824,109 shares of the biotechnology company’s stock valued at $12,440,000 after buying an additional 1,124,338 shares in the last quarter. Finally, Prosight Management LP increased its position in shares of Pieris Pharmaceuticals by 141.2% in the second quarter. Prosight Management LP now owns 1,360,000 shares of the biotechnology company’s stock valued at $6,895,000 after buying an additional 796,237 shares in the last quarter. Institutional investors and hedge funds own 64.93% of the company’s stock.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Featured Article: Risk Tolerance

Analyst Recommendations for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply